Treating Patients with NSCLC and Actionable Mutations Following Progression

Opinion
Video

Isabel Preeshagul, DO, MBS, and the Oncology Brothers discuss the treatment of patients with NSCLC and actionable mutations following progression on first-line therapy.

Recent Videos
The Onc Brothers feature one guest in this series.
The Onc Brothers feature one guest in this series.
The Onc Brothers feature one guest in this series.
The Onc Brothers feature one guest in this series.
The Onc Brothers feature one guest in this series.
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Related Content
Surgeons, radiation oncologists, and medical oncologists gathered to discuss treatment options and approaches for NSCLC.

A Multidisciplinary Approach to Treating Resectable NSCLC

Gregory Gan, MD, PhD;Alykhan Nagji, MD;Krishna Reddy, MD, PhD;Vinay Raja, MD
September 4th 2024
Article

Surgeons, radiation oncologists, and medical oncologists gathered to discuss treatment options and approaches for NSCLC.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology

Terence T. Sio, MD, MS
June 3rd 2024
Podcast

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Favorable recurrence-free survival and overall survival outcomes were not observed in the overall patient cohort receiving adjuvant chemotherapy for advanced NSCLC.

Adjuvant Chemotherapy May Have Survival Benefit in Stage III Locally Advanced NSCLC

Roman Fabbricatore
September 3rd 2024
Article

Favorable recurrence-free survival and overall survival outcomes were not observed in the overall patient cohort receiving adjuvant chemotherapy for advanced NSCLC.

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery

Richard Lazzaro, MD
April 22nd 2024
Podcast

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

NSCLC and CSCC Trials Discontinued Due to No Efficacy Benefit With Pembrolizumab/SBRT

NSCLC and CSCC Trials Discontinued Due to No Efficacy Benefit With Pembrolizumab/SBRT

Ariana Pelosci
August 29th 2024
Article

Trials assessing NSCLC and cutaneous squamous cell carcinoma were discontinued due to no benefit observed or improvement noted with the primary end points.

The EGFR-MET bispecific antibody amivantamab in combination with chemotherapy yielded a survival benefit compared with chemotherapy alone for EGFR-mutated NSCLC.

European Commission Approves Amivantamab Combo for EGFR-mutated NSCLC

Roman Fabbricatore
August 28th 2024
Article

The EGFR-MET bispecific antibody amivantamab in combination with chemotherapy yielded a survival benefit compared with chemotherapy alone for EGFR-mutated NSCLC.